Ticker Details
uniQure N.V. Ordinary Shares uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
IPO Date:	March 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.02B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.66 | 2.97%
Avg Daily Range (30 D):	$0.86 | 6.07%
Avg Daily Range (90 D):	$0.85 | 4.42%

Institutional Daily Volume
Avg Daily Volume:	.67M
Avg Daily Volume (30 D):	4.03M
Avg Daily Volume (90 D):	2.7M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	99
Avg Trade Size (Sh.) (90 D):	89

Institutional Trades
Total Institutional Trades:	3,251
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$2.07M
Avg Institutional Trade (90 D):	$2.48M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.1M
Avg Closing Trade (30 D):	$3.64M
Avg Closing Trade (90 D):	$4.07M
Avg Closing Volume:	102.45K

News

Apr 10, 2026 @ 5:53 PM INVESTOR DEADLINE: uniQure (QURE) Investors with S... Source: Hagens Berman

Apr 8, 2026 @ 8:57 PM INVESTOR DEADLINE: uniQure (QURE) Investors with S... Source: Hagens Berman

Apr 8, 2026 @ 1:47 AM uniQure N.V. Securities Fraud Class Action Result ... Source: Kahn Swick & Foti, Llc

Apr 7, 2026 @ 7:59 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: Pomerantz Llp

Apr 7, 2026 @ 7:49 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: Pomerantz Llp

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.46	$-.56	$-3.46
Diluted EPS	$-3.46	$-.56	$-3.46
Revenue	$16.1M	$5.57M	$16.1M
Gross Profit	$14.41M	$5.13M	$14.41M
Net Income / Loss	$-198.97M	$-37.09M	$-198.97M
Operating Income / Loss	$-185.35M	$-51.12M	$-185.35M
Cost of Revenue	$1.69M	$.44M	$1.69M
Net Cash Flow	$-78.53M	$-516.75M	$-78.53M
PE Ratio